American Society of Addiction Medicine

This Week in Addiction Medicine from ASAM

American Society of Addiction Medicine

  • Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States

Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States

Tuesday 10th September 2024

Explore racial disparities in buprenorphine treatment durations and other key addiction medicine topics in this insightful episode from ASAM.
5 minutes
Informative
Educational
Compassionate
Eye-opening
Supportive

About this podcast

This Week in Addiction Medicine from ASAM
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

Unpacking Racial Disparities in Buprenorphine Treatment

Episode Overview

  • State-level racial disparities in buprenorphine treatment durations.
  • Impact of buprenorphine on pregnant patients.
  • Interventions reducing drug-related harms among incarcerated individuals.
  • Mental health disorders linked to overdose deaths.
  • Household composition's effect on substance use among young adults.
We need to address these systemic inequities to ensure everyone has access to effective addiction treatment
In this episode of 'This Week in Addiction Medicine', the American Society of Addiction Medicine dives into the critical issue of racial and ethnic disparities in buprenorphine treatment duration across the United States. The episode highlights a study that analysed over nine million buprenorphine prescriptions from 2011 to 2020, revealing stark differences in treatment durations among various racial and ethnic groups at the state level.
Particularly, 21 states showed longer treatment durations for White individuals, with eight states displaying similar trends for treatments lasting 180 days or more. This discussion is vital for understanding and addressing systemic inequities in addiction treatment. The episode also explores several other significant studies, including the impact of buprenorphine during pregnancy, interventions to reduce drug-related harms among incarcerated individuals, and the effects of household composition on substance use among young adults.
The hosts provide a comprehensive overview of these findings, offering valuable insights for healthcare providers, policymakers, and anyone interested in addiction medicine. Tune in to gain a deeper understanding of these pressing issues and their implications for improving addiction treatment and outcomes.
alcoholfree.com
Published by The Mindful Drinking Company Limited
4 Providence Court, Pynes Hill, Exeter, Devon, EX2 5JL, England
Registered in England and Wales.
Company Number: 1195057. Vat Number: GB320915135.
Registered address as above.
© Copyright 2005-2025 The Mindful Drinking Company Limited.
All Rights Reserved.
alcoholfree.com is a participant in the Amazon Associates Programme, an affiliate advertising programme designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.co.uk. As an Amazon Associate, we earn from qualifying purchases.